Biotechnology

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

With promising early data and a unique brain delivery method, AviadoBio's AVB-101 trial offers new hope for patients with FTD-GRN, a devastating disease.

The neurotech pioneer reports strong sales for its spinal cord injury therapy, secures key FDA approvals, and plans for major US stock market entry.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

Sangamo pushes a promising Fabry disease therapy toward the FDA while a cash crunch forces a strategic pivot to brain-targeting neurological cures.

With improved financials and progress on therapies for cannabis use disorder and Down syndrome, the French biotech charts a confident course for the future.

Formerly Asha Therapeutics, the biotech rebrands with top talent and an AI platform that designs novel medicines from scratch for humanity's toughest diseases.

Shanghai names Sanyou Bio a top municipal tech center, validating its AI-powered antibody library that's reshaping global drug R&D and fueling regional innovation.

The biotech firm's oversubscribed funding round will accelerate its universal flu shot and a diverse pipeline targeting cancer, malaria, and Alzheimer's.

Danish firm Evaxion, backed by the Gates Foundation, uses its AI platform to design a next-gen polio vaccine, aiming to end the disease for good.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

German CDMO Vetter wins a prestigious, client-voted award, underscoring its pivotal role and massive €2 billion investment in the world of injectable biologics.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

Aurinia Pharmaceuticals' deal for Kezar Life Sciences hinges on zetomipzomib, a promising but risky drug poised to tackle a rare autoimmune liver disease.

Japanese pharma giant Meiji Seika Pharma backs Centivax's quest for a universal flu vaccine, a move that could revolutionize global pandemic preparedness.

A Georgia firm's painless patch technology earns top honors, promising to revolutionize medicine delivery and solve critical global health challenges.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.